# NMD Pharma A/S

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nmd-pharma-a-s

- Industry: Biotechnology
- Headquarters: Aarhus, Denmark
- Website: www.nmdpharma.com/
- Total disclosed funding: $131M
- Latest round: Series B (Nov 15, 2023)
- Investors on record: 6

## About

NMD Pharma A/S, based in Denmark, is focused on developing innovative therapeutics for neuromuscular diseases, particularly through small molecule inhibitors that target skeletal muscle ion channels.Founded in 2015 and headquartered in Aarhus, Denmark, NMD Pharma A/S specializes in the development of therapeutics for neuromuscular disorders. The company has engaged in 4 significant funding deals, with the latest funding round, a Series B, completed on November 15, 2023, where they raised EUR 75 million led by Jeito Capital and supported by other notable investors such as Novo Holdings and Roche Venture Fund. Thomas Pedersen serves as the CEO, bringing his expertise to steer the company in its endeavors.NMD Pharma specializes in the discovery and development of innovative therapeutics aimed at treating neuromuscular diseases. The company’s primary focus is on small molecule inhibitors targeting skeletal muscle-specific ClC-1 ion channels, which are implicated in conditions characterized by muscle weakness and fatigue, such as myasthenia gravis, spinal muscular atrophy, Charcot-Marie-Tooth disease, and sarcopenia. These products aim to enhance muscle function and improve the quality of life for patients suffering from these debilitating conditions. The end users of their products are primarily patients diagnosed with neuromuscular disorders, while healthcare providers and institutions serve as clients, facilitating the delivery of these advanced treatment options. NMD Pharma's therapeutics are positioned for clinical trials in various international markets, including Europe and North America.NMD Pharma successfully raised EUR 75 million in a Series B funding round, underscoring the company's financial backing to propel its clinical development of ClC-1 inhibitor drugs. Revenue generation for NMD Pharma is expected to come from partnerships with healthcare providers and pharmaceutical distributors, as well as potential collaborations with larger pharmaceutical companies for further development and commercialization of its products. The structure of transactions may include B2B arrangements whereby hospitals and clinics purchase the therapeutic products directly, alongside structured partnerships that involve revenue-sharing agreements based on the therapeutic outcomes achieved.In November 2023, NMD Pharma A/S raised EUR 75 million in Series B funding, which will be used to complete Phase 2 clinical studies of its first-in-class ClC-1 molecule inhibitor NMD670, targeting conditions such as myasthenia gravis, spinal muscular atrophy, and Charcot-Marie-Tooth disease. The company plans to expand its market presence in Europe and North America as it progresses through clinical trials, seeking to address the global need for effective treatments in the field of neuromuscular diseases.

## Funding rounds

- Series B, Nov 15, 2023, $82M — Novo Holdings, Lundbeckfond Ventures, Roche Venture Fund, Inkef, Jeito Capital
- Series A, Mar 23, 2018, $47M — Novo Holdings, Lundbeckfond Ventures, Roche Venture Fund, Inkef
- Seed, Jun 13, 2016, $3M — Novo Holdings, Lundbeckfond Ventures, CAPNOVA

## Investors

- Novo Holdings — Seed, Series A, Series B
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Seed, Series A, Series B
- CAPNOVA (https://capitalatlas.ai/funds/capnova) — Seed
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A, Series B
- Inkef (https://capitalatlas.ai/funds/inkef) — Series A, Series B
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series B